Bio-Techne Corporation (TECH)

Over the past six months, Bio-Techne's stock has experienced movements influenced by earnings reports and analyst sentiment. In Q4 fiscal 2025, Bio-Techne exceeded expectations, leading to initial confidence. Analyst sentiment has been positive, with several upgrades in late 2025. More recently, Bio-Techne reported its Q2 fiscal 2026 results with flat revenue year-over-year, though adjusted operating margin increased. The stock has faced headwinds due to sluggish spending from biopharma and biotech customers. In the fourth quarter of 2025, Hollow Brook Wealth Management LLC divested its entire position in Bio-Techne. As of April 6, 2026, the stock price was $53.80, and its 52-week range was $46.01 to $72.16.

Bio-Techne experiences some seasonality in its business due to the vacation and academic schedules of its global customer base, particularly for its Protein Sciences segment. There is also some seasonality for the ExosomeDx Prostate test, as patients tend to avoid scheduling medical appointments during the summer and other holidays. Sales for the Diagnostics Reagents division can be unpredictable and not necessarily based on seasonality.

Bio-Techne Corp. is a life sciences company operating in the Healthcare sector, specifically in the Biotechnology industry. The company is divided into two primary segments: Protein Sciences, which focuses on biological reagents and proteomic analytical tools, and Diagnostics and Spatial Biology, which offers diagnostic products such as tissue-based in-situ hybridization assays and genetic and oncology kits. Bio-Techne has an extensive catalog of over 500,000 products, with 95% manufactured in-house.

Bio-Techne is headquartered in Minneapolis, Minnesota, U.S., and has a global presence with over 3,000 employees across 34 locations worldwide. The United States accounts for approximately 55% of its revenue. The company also has significant operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the remaining 5% from the rest of the world. It maintains offices throughout North America, Europe, and Asia, including subsidiaries in China and Hong Kong.

Bio-Techne maintains a strong reputation for its proteomic reagents and instruments. In the past year, the company has made announcements that positively impact its brand reputation by highlighting innovation and market expansion, including advancing spatial biology with the modular expansion of its COMET™ Suite, its Ella Platform achieving CE-IVD Marking, expanding its 3D Stem Cell and Organoid Culture Portfolio, and launching Simple Plex Ultra-Sensitive Assays on the Ella Platform. The company's commitment to quality and comprehensive support for its products also underpins its reputation. Data breaches could lead to negative publicity and damage its reputation.

Bio-Techne's shareholder base is primarily led by major institutional investors, who own 110.07% of the company, while Bio-Techne insiders hold 2.49%. The Vanguard Group, Inc. is the largest individual shareholder, owning 11.38% of the company. Other major institutional owners include BlackRock Institutional Trust Company, State Street Investment Management, Morgan Stanley, and Wellington Management Group Llp. Individual insider ownership remains under 5% overall.